Erik Hedrick
Overview
Explore the profile of Erik Hedrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burdock G, Hedrick E
Arch Toxicol
. 2024 Jul;
98(10):3209-3214.
PMID: 39017690
Are all food ingredients, dietary supplement ingredients and even foods, required to meet the same safety standards? Are they all equally safe? If so, then why do the various categories...
2.
Safe S, Shrestha R, Mohankumar K, Howard M, Hedrick E, Abdelrahim M
World J Gastroenterol
. 2021 Nov;
27(38):6387-6398.
PMID: 34720529
Specificity protein (Sp) transcription factors (TFs) Sp1, Sp3 and Sp4, and the orphan nuclear receptor 4A1 (NR4A1) are highly expressed in pancreatic tumors and Sp1 is a negative prognostic factor...
3.
Hedrick E, Mohankumar K, Lacey A, Safe S
Mol Cancer Res
. 2019 Aug;
17(11):2221-2232.
PMID: 31462501
Nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in rhabdomyosarcoma (RMS), and inactivation of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonist 1,1-bis(3'-indoly)-1-(p-hydroxy-phenyl)methane (DIM-C-pPhOH) has antiproliferative and proapoptotic effects on RMS...
4.
Hedrick E, Li X, Cheng Y, Lacey A, Mohankumar K, Zarei M, et al.
Breast Cancer Res Treat
. 2019 May;
177(1):29-40.
PMID: 31119568
Background: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in...
5.
Lacey A, Hedrick E, Cheng Y, Mohankumar K, Warren M, Safe S
Mol Cancer Ther
. 2018 Sep;
17(12):2756-2766.
PMID: 30190424
Alveolar rhabdomyosarcoma (ARMS) patients have a poor prognosis, and this is primarily due to overexpression of the oncogenic fusion protein PAX3-FOXO1. Results of RNA-sequencing studies show that PAX3-FOXO1 represses expression...
6.
Hedrick E, Mohankumar K, Safe S
Mol Cancer Res
. 2018 Aug;
16(12):1991-2002.
PMID: 30072581
TGFβ induces migration of lung cancer cells (A549, H460, and H1299), dependent on activation of c-Jun N-terminal kinase (JNK1), and is inhibited by the JNK1 inhibitor SP600125. Moreover, TGFβ-induced migration...
7.
Safe S, Abbruzzese J, Abdelrahim M, Hedrick E
Cancer Prev Res (Phila)
. 2018 Mar;
11(7):371-382.
PMID: 29545399
Specificity protein (Sp) transcription factors (TFs) such as Sp1 are critical for early development but their expression decreases with age and there is evidence that transformation of normal cells to...
8.
Cheng Y, Imanirad P, Jutooru I, Hedrick E, Jin U, Rodrigues Hoffman A, et al.
PLoS One
. 2018 Feb;
13(2):e0192264.
PMID: 29389953
Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a long non-coding RNA (lncRNA) that is a negative prognostic factor for patients with pancreatic cancer and several other tumors. In this study, we...
9.
Hedrick E, Lee S, Doddapaneni R, Singh M, Safe S
Mol Cell Biol
. 2017 Aug;
37(18).
PMID: 28847971
No abstract available.
10.
Hedrick E, Safe S
Mol Cell Biol
. 2017 Jul;
37(18).
PMID: 28674186
Transforming growth factor β (TGF-β)-induced migration of triple-negative breast cancer (TNBC) cells is dependent on nuclear export of the orphan receptor NR4A1, which plays a role in proteasome-dependent degradation of...